Trial-Results center  
Clinical trial results database Feedback    Home

This trial is included in the following systematic reviews and meta-analyses:

atrial fibrillation - prevention - patients without history of AF (primary prevention)  


Related trials

GISSI HF (subgroup and ancillary study), 2009 - rosuvastatin vs placebo

ARMYDA-3, 2006 - atorvastatin vs placebo

Chello, 2006 - atorvastatin vs placebo

LIFE, 2005 - losartan vs atenolol

CHARM, 2005 - candesartan vs placebo

Val-HeFT, 2003 - valsartan vs placebo

GISSI-3, 2003 - lisinopril vs placebo

SOLVD, 2003 - enalapril vs placebo

MIRACL, 2001 - atorvastatin vs placebo

TRACE, 1999 - trandolapil vs placebo

VA HIT, 1999 - gemfibrozil vs placebo



See also:

  • All atrial fibrillation clinical trials
  • All clinical trials of prevention
  • All clinical trials of enalapril
    		•  

    SOLVD study, 2003

    Treatments

    Studied treatment enalapril
    Control treatment placebo

    Patients

    Patients Heart failure
    Inclusion criteria patient with history of AF excluded; sinus rhythm at baseline

    Method and design

    Randomized effectives 186 / 188 (studied vs. control)
    Follow-up duration 2.9 y


    Results

    Endpoint Studied treat.
    n/N     Control treat.
    n/N     Graph RR [95% CI]

    atrial fibrillation

    10 / 186
         45 / 188
         0,22 [0,12;0,43]     0 2 1.0

    Relative risks
    Endpoint Events (%) Relative Risk 95% CI Endpoint definition
    in the trial    		 Ref
    Studied treat. Control treat.
    atrial fibrillation 10 / 186 (5,4%) 45 / 188 (23,9%) 0,22 [0,12;0,43]   11053 
    The primary endpoint (if exists) appears in blod characters
    Reference(s) used for data extraction:
  • 11053: Anand K, Mooss AN, Hee TT, Mohiuddin SMMeta-analysis: inhibition of renin-angiotensin system prevents new-onset atrial fibrillation.Am Heart J 2006;152:217-22

    • Endpoint studied treat. control treat. mean diff

    Absolute risk reduction
    Endpoint Events rate Absolute risk
    reduction (ARR)
    Studied treat. Control treat.
    atrial fibrillation 5,38% 23,94% -185,6‰


    Reference(s)

    Trials register # NA
    • Vermes E, Tardif JC, Bourassa MG, Racine N, Levesque S, White M, Guerra PG, Ducharme A. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials.. Circulation 2003;107:2926-31
      Pubmed | Hubmed | Fulltext

    (c) 2004-2010 TrialResults-center - All Rights Reserved

    Tweet this  |  notify a friend